Compound synthesis

Experimental Procedures
Solvents and reagents were purchased from suppliers and used without any further purification. Normal phase chromatography was conducted using a Teledyne ISCO, CombiFlash Rf system with silica gel prepacked columns (RediSep® Rf) and TLC plates pre-coated with silica gel 60 F 254 on aluminum (Merck KGaA) with detection by UV (254 nm). The pH of solutions were measured using pHix 0-14 paper (FisherBrand). LC/MS was conducted using: Waters Acquity UPLC with Waters SQ detector; with a Acquity HSS T3 1.8 µm 2.1 x 50 mm column; eluting with gradients of aqueous acetonitrile containing formic acid and ammonium acetate modifiers. Proton, fluorine and carbon NMR experiments were performed using Bruker Ultrashield 400, Varian Mercury 400 MHz and 500 MHz DRX Bruker CryoProbe instruments. Chemical shifts (δ) are quoted in ppm relative to residual proton peaks in solvent. The multiplicity of the signals are indicated as s-singlet, d-doublet, t-triplet, q-quartet, p-pentet, hept-heptet, m-multiplet, or br-broad. Coupling constants are quoted in Hz to one decimal place. For NMR, the solvents were chosen according to the position of solvent peaks in the spectra and based upon the solubility of the measured compound. Within this text, room temperature (RT) is defined as 19 -25 °C.
The term in vacuo is used to describe solvent removal by Büchi rotary evaporation between 17 and 40 °C, at 20 -500 mbar unless otherwise stated.
Compounds 5 and 6 were prepared as described in reference 22 in the main text. Step Step 2: 4-fluoro-2-isobutoxy-1-nitrobenzene. A solution of isobutanol (5.80 ml, 62.9 mmol) in THF (100 ml) under argon was cooled in an ice bath and treated portion wise with potassium tert.butoxide (9.17 g, 82 mmol). After complete addition the bath was removed and the reaction mixture was stirred for 30 min. The reaction mixture was cooled to -78 °C and then 2,4-difluoronitrobenzene (6.89 ml, 62.9 mmol) was added via syringe at such a rate that the internal temperature did not exceed -65 °C. After complete addition the dark brown reaction mixture was stirred 5 min and then the cooling bath was removed and the reaction mixture was stirred for 1 h. The reaction mixture was poured into water, extracted 2x with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to give the desired product as red oil (13.08 g, 61.3 mmol, 98 % yield), which was used without further purification. 1 Step 3: 1-(3-isobutoxy-4-nitrophenyl)-N,N-dimethylpiperidin-4-amine. A solution of 4-fluoro-2-isobutoxy-1-nitrobenzene (1.5 g, 7.04 mmol) and 4-dimethylaminopiperidine (2.26 g, 17.59 mmol) in DMF (14 ml) was heated to 60 °C and stirred for 1 h. The reaction was cooled to RT, diluted with Et 2 O, washed with saturates aqueous NaHCO 3 , water and brine, dried over Na 2 SO 4 filtered and concentrated. The residue was dried under vacuum to give the desired product (2.19 g, 97 % yield) as an orange oil, which solidified upon standing to give a yellow solid. 1 6 .57 (dd, J = 9.5, 2.5 Hz, 3H), 7.87 (d, J = 9.3 Hz, 3H).
Step 4: 1-(4-amino-3-isobutoxyphenyl)-N,N-dimethylpiperidin-4-amine. A solution of 1-(3-isobutoxy-4-nitrophenyl)-N,N-dimethylpiperidin-4-amine (2.19 g, 6.81 mmol) in MeOH (25 ml) and THF (25 ml) under argon was treated with Pd/C (0.218 g, 0.204 mmol), the flask was flushed with H 2 and the reaction mixture was stirred under a positive pressure of H 2 (balloon) for 2 h. The flask was flushed with argon for 5 minutes. The suspension was then filtered and concentrated under vacuum to give the desired product (1.93 g, 92 % yield) as a brown-purple solid. 1 Step 5:
A mixture of (1S,2S,3R,4R)-3-(2-chloro-5-cyanopyrimidin-4-ylamino)bicyclo[2.2.1]hept-5-ene-2-carboxamide (47 mg, 0.163 mmol) and 1-(4-amino-3-isobutoxyphenyl)-N,N-dimethylpiperidin-4-amine (50 mg, 163 mmol) in ethylene glycol monomethyl ether (0.33 ml) was heated to 80 °C for 4.5 h. Saturated aq NaHCO 3 solution was added to the cooled reaction mixture, which was then extracted 3x with CH 2 Cl 2 , the combined organic extracts dried over Na 2 SO 4 and evaporated. The crude product was purified by normal phase chromatography, eluting with a gradient from CH 2 Cl 2 to 10% methanol in CH 2 Cl 2 containing 0.5% Et 3 N, to give the desired product (78 mg, 79%). 1 Step 1: tert-butyl 5-amino-3-(3,5-dimethoxyphenethyl)-1H-pyrazole-1-carboxylate. Di-tert-butyl dicarbonate (3.2 ml, 13.8 mmol) was added to a biphasic mixture of 5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-amine (3.0 g, 12.1 mmol), in CH 2 Cl 2 (120 ml) and aqueous KOH (25 ml 4M, 100 mmol) at room temperature and stirred for 18 hours. The phases were separated and the organic layer washed with water then brine, dried over Na 2 SO 4 and evaporated. The crude product was purified by normal phase chromatography, eluting with a gradient from heptane to 1:1 EtOAc/heptane, to give the desired product as an off-white solid (3.43 g, 77% yield). 1 Step Step 5: 2-acrylamido-N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)benzamide 8. Trifluoroacetic acid (1.5 ml, 19.5 mmol) was added to a solution of tert-butyl 3-(2-acrylamidobenzamido)-5-(3,5-dimethoxyphenethyl)-1H-pyrazole-1-carboxylate (673 mg, 1.29 mmol) in CH 2 Cl 2 , cooled with an ice bath. The reaction mixture was stirred for 30 minutes, then partitioned between saturated NaHCO 3 and CH 2 Cl 2 , extracted 3x with CH 2 Cl 2 , the combined organic layers were washed with water, dried over Na 2 SO 4 and evaporated. The crude product was suspended in i Pr 2 O (50 ml) and heated with sonication, then cooled and filtered to give the desired product as a white crystalline solid (430 mg, 78 % yield). 1 3-chloro-N-(6-chloro-3-nitropyridin-2-yl)-5-(trifluoromethyl)pyridin-2-amine 9. A solution of 2,6-dichloro-3-nitropyridine (1.9 g, 10 mmol) was added dropwise over 30 minutes to a suspension of powdered potassium hydroxide (1.2 g, 20 mmol) in a solution of 3-chloro-5-(trifluoromethyl)pyridin-2-amine (1.9 g, 10 mmol) in THF (40 ml) at 0 °C. The reaction mixture was allowed to warm to room temperature, diluted with water (100 ml), and the pH adjusted to 2-3 by the addition of conc. hydrochloric acid. The mixture was extracted 4x with EtOAc, the combined organic layers washed with water, dried over MgSO 4 , and evaporated. Purification of the crude product was carried out by normal phase chromatography (250 g Kieselgel), eluting with 1:3 diethyl ether/hexane, to give the desired product as a yellow crystalline solid (2.1 g, 60% yield Compounds 10, 12 and 13 were prepared as described previously. S2 The acid 12 is obtained as an over oxidation product in the selenium dioxide oxidation used to prepare 10. Step 1: 2-methyl-N-(4-(trifluoromethyl)phenyl)quinoline-8-carboxamide. A mixture of 2-methylquinoline-8-carboxylic acid (50 mg, 0.267 mmol), 4-(trifluoromethyl)aniline (43 mg, 0.267 mmol), HATU (102 mg, 0.267 mmol), and N-methyl morpholine (29 μl, 0.267 mmol) in DMF (2 ml) was stirred at RT for 16 hours. The reaction mixture was diluted with EtOAc, washed 2x with saturated aqueous NaHCO 3 and 1x with brine, the organic phase dried over Na 2 SO 4 and evaporated. The crude product was purified by normal phase chromatography, eluting with a gradient from heptane to 1:3 EtOAc/heptane, to give the desired product as a white solid (48 mg, 52% yield). 1 Step 2: 2-formyl-N-(4-(trifluoromethyl)phenyl)quinoline-8-carboxamide 14. Selenous acid (37 mg, 0.289 mmol) was added to a solution of 2-methyl-N-(4-(trifluoromethyl)phenyl)quinoline-8-carboxamide (48 mg, 0.145 mmol) in 1,4-dioxane (4 ml), and the mixture heated at reflux under N 2 for 5 hours. The reaction mixture was diluted with EtOAc, washed 2x with saturated aqueous NaHCO 3 and 1x with brine, the organic phase dried over Na 2 SO 4 and evaporated. The crude product was purified by normal phase chromatography, eluting with a gradient from heptane to 7:3 EtOAc/heptane, to give the desired product as a beige solid (26 mg, 50% yield). 1 At the initiation of this project, no crystal structure of the kinase domain of FGFR4 was available. Therefore, to support the project a model of this domain was generated by homology to the crystal structure of infigratinib in complex with FGFR1 (PDB code: 3TT0). The sequences of the human FGFR1 and FGFR4 kinases were obtained from SWISS-PROT, S4 entries P11362 and P22455, respectively. The sequences were aligned using T-Coffe. S5 On the basis of the resulting alignment, the 3D structure of the FGFR4 kinase was modeled using the 'WHAT IF' program with the default parameters (PIRPSQ module, BLDPIR command). S6 Modeling and docking using the homology model was performed with a version of MacroModel enhanced for graphics by A. Dietrich. S7 The compounds were manually constructed and docked in the ATP site of the model and the resulting ligand-protein complexes energy-minimized using the AMBER*/H 2 O/GBSA force field.
Ab initio conformational calculations for compound 10 were performed in Jaguar (Schrödinger Inc.) at the B3LYP/6-31G** level with full geometry optimization. The figures for the structural models were prepared using PYMOL (Schrodinger, Inc.). Modeling the interactions of 6 and 7 with the C552A variant of FGFR4
The above structure of FGFR4 in which the cysteine at position 552 was switched for alanine was used to model the interactions with compounds 6 and 7. In contrast to the methoxy analogue 6, the isobutoxy analogue 7 is able to fill the additional space created by the C552A variant to maintain the hydrophobic surface shielding the hinge interaction. The above structure of FGFR4 was used to model the covalent adduct with 8 following a Michael reaction with Cys552, and the minimised structure is shown in Figure S5 below. Following the thioether formation the key interactions with the hinge and back-pocket, made by the parent compound, are retained in the adduct, as outlined in Figure 8 in the main text for the Cys477 covalent adduct. Figure S5 . Model of 8 covalently bound to the middle-hinge Cys552 of the FGFR4 kinase domain.
The above structure of FGFR4 was used to model the covalent adduct with 9 following a S N Ar reaction with Cys477 in two conformations: 1) with the P-loop in the active hairpin conformation; 2) with the Ploop in the disordered conformation found in the X-ray structure of 8, shown in Figure 8 in the main text. The minimised structures are shown in Figure S6 , and in neither of the structures does the bipyridyl moiety interact within the ATP-pocket. Figure S6 : Models of compound 9 bound to FGFR4 after reaction with Cys477 considering two possible conformations of the P-loop.
Biochemical FGFR screening
The biochemical assays used to assess the FGFR family and FGFR4 cysteine to alanine variant activities are described below. Transfection and Virus generation: Sf9 insect cells were co-transfected with construct DNA (gene of interest in transfer vector) and flashBac DNA using the protocol form supplier of flashBac (Oxford Expression Technologies). Virus generated were collected on day 5. Sf9 cells (3 ml) grown and maintained in log phase (1.5 x 10 6 cell per ml) were infected with V0 virus (120 μl) and incubated at 27 °C for 48 h with 200 rpm in a shaker incubator. Culture was aseptically centrifuged at 1500 rpm for 10 min to recover supernatant as V1 virus stock. Working stock of virus was generated by infecting 100 ml of Sf9 cells in log phase with 100 ul of V1 virus. Culture was centrifuged 48 h post infection and clear supernatant was stored at 4 °C as V2 virus stock.
Expression: 1 L of Sf9 cells at 2 x 10 6 cells per ml in a 3 L Erlenmeyer flask was infected with 10 ml of V2 virus generated above. Infected culture was incubated at 27 °C for 48 h with 90 rpm in a shaker incubator. Cell pellets were harvested by centrifuging the culture at 1500 rpm for 15 min and stored at -80 °C.
Purification: Pellet from 2 L of culture was thawed at room temperature and suspended in lysis buffer (50 mM Tris pH7.6, 400 mM NaCl, 10% Glycerol v/v, 3 mM TCEP supplemented with EDTA-free protease inhibitor, Roche). Each gram of pellet was suspended in 8 ml of lysis buffer. The suspension was homogenized by passing through a French press 3 times. Clarified supernatant was loaded on Ni-NTA Superflow Cartridge (Qiagen) using AKTA purifier system. Target protein was eluted using lysis buffer supplemented with 200 mM imidazole. His tag was removed by using appropriate protease cleavage and protein is dephosphorylated using Lambda phosphatase in presence of 2 mM MnCl 2 . Partially purified protein is diluted to achieve final NaCl concentration to 100 mM in IEX buffer (20 mM Tris pH 7.6, 10% glycrol, 1 mM TCEP) and loaded on MonoQ column and fractionated by using NaCl gradient from 100 to 400 mM in 20 column volume. Fraction corresponding to target protein was collected, concentrated and loaded on gel filtration column (HiLoad 16/60 Superdex 75 pg) pre-equilibrated with 20 mM Tris pH7.6, 150 mM NaCl, 3 mM TCEP, 1 mM EDTA. Correct mass of the purified protein was determined by mass spectrometry. Aliquots are flash frozen and stored at -80 °C.
FGFR biochemical assays (Tables 1 and 2 Liquid handling and incubation steps were done on an Innovadyne Nanodrop Express equipped with a robotic arm (Thermo CatX, Caliper Twister II) and an incubator (Liconic STX40, Thermo Cytomat 2C450). The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 µL per well of enzyme solution (50 mM HEPES pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 10 mM beta-glycerolphosphate, 10 µM sodium orthovanadate with enzyme specific enzyme / MgCl 2 / MnCl 2 concentrations, Table S1 ) and 4.5 µL per well of peptide/ATP-solution (4 µM peptide, FGFR1-3 assays used the 5-Fluo-Ahx-EEPLYWSFPAKKK-CONH 2 peptide substrate, and the FGFR4 assays used the 5-Fluo-Ahx-KKKKEEIYFFFG-NH 2 peptide substrate, 50 mM HEPES pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 10 mM betaglycerolphosphate, 10 µM sodium orthovanadate with enzyme specific ATP / MgCl 2 / MnCl 2 concentrations, Table S1 ). Kinase reactions were incubated at 30 °C for 60 minutes and subsequently terminated by addition of 15 µl per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Plates with terminated kinase reactions were transferred to the Caliper LC3000 system for reading. Phosphorylated and unphosphorylated peptides were separated using the Caliper microfluidic mobility shift technology. Briefly, samples from terminated kinase reactions were applied to the chip. Analytes are transported through the chip by constant buffer flow and the migration of the substrate peptide is monitored by the fluorescence signal of its label. Phosphorylated peptide (product) and unphosphorylated peptide (substrate) are separated in an electric field by their charge/mass ratio. Kinase activities were calculated from the amounts of formed phospho-peptide. IC 50 values were determined from percent inhibition values at different compound concentrations by non-linear regression analysis. High throughput screening campaign (HTS): A time-resolved fluorescence energy transfer (TR-FRET) assay was used in a 1536-well format with the non-phosphorylated wild-type FGFR4 kinase domain (442-753) to screen 1.4 million compounds at a concentration of 25 μM. In more detail, the final assay volume was 5 μl in buffer (50 mM Hepes, pH 7.4, 0.05% CHAPS, 0.02% bovine serum albumin, 1 mM dithiothreitol, 10 mM MgCl 2 , 1 mM MnCl 2 ) which contained: 10 nM FGFR4; 50 μM ATP; 500 nM biotin-labelled CSKtide substrate; EDTA 10 mM; 5 nM streptavidin-allophycocyanin; 1.5 mM Eu-labelled antiphosphotyrosine antibody. FGFR4 and test compounds were first incubated for 30 minutes before the addition of ATP, after a further 60 minutes the CSKtide substrate was added followed by the detection mix after a further 15 minute incubation. The plates were then read with a Perkin Elmer En Vision Multiplate Reader after a further 40 minute incubation period. From this screen 18.8 thousand hits were chosen for confirmation at four concentrations using the HTS FGFR4 assay and also the FGFR2 assay, described above, as a selectivity screen. Finally 4400 hits were selected for IC 50 determinations using the FGFR4 and the FGFR2 assays.
Kinase selectivity profiles of compounds 5 -10.
Biochemical kinase assays: Assays were performed with the indicated purified kinases, or recombinant kinase-domains, in the absence and with increasing concentrations of the test compounds by measuring the incorporation of 33 P, from [γ 33 P]ATP, into appropriate substrates. All values are from duplicate measurements, and average values are shown from 1 to 3 separate experiments, Table S2 .
The Caliper assays are typically run at ATP K m for the assay specific enzyme concentration. 
> 10 1.2 > 10 > 10 > 10 > 10 n.d. = not determined.
Selected profiling data for compound 7
The profile of compound 7 made it suitable for use as a selective non-covalent FGFR4 tool compound, and selected data are included below.
Compound 7 was a potent inhibitor of FGFR4-phosphorylation in an FGFR4-dependent Ba/F 3 cell line, S8 and inhibited proliferation of the FGF19/FGFR4 expressing HCC cell lines: HUH7, JHH7, and Hep3B. Data are shown in Table S3 . A pharmacokinetic study in the mouse was conducted as outlined below, and showed 7 to be orally bioavailable. Data are shown in Table S4 Blood levels of unchanged 7 after oral administration to conscious mice. Shown are means ± standard error of the mean (n = 3).
FGFR4 mass spectroscopy studies
Mass spectrometry determination of covalent adduct formation:
20-30 μM of dephosphorylated human FGFR4 (442-753) wild type, C552A variant, or C477A variant, was prepared prior to MS by passing an aliquot over a NAP-5 column (17-0853-01, GE Healthcare) to remove glycerol. Fractions consisting of 100 μL aliquots were collected using Low-Bind protein eppendorf tubes on ice (Z666491 Sigma). The elution buffer was composed of 50 mM Tris pH 8.0; 150 mM NaCl; 1 mM EDTA (reagents were purchased from Sigma). The fractions were quantified using the Nanodrop Instrument by Witec. Each reaction was incubated with compound for 2 h at RT in a 10 μL sample containing 2-4 μg of total protein, with a final DMSO content of 5% (SERVA 20835). The compound concentrations were set at 0 μM to 200 μM using a 1 to 2 dilution factor. A Waters LCT Premier XE mass spectrometer coupled with an Agilent 1100 HPLC was used for quantification with the following conditions: The intact protein complex analysis confirmed the presence of a single covalent adduct of 8 with the FGFR4 protein.
For the analysis of tryptic peptides of FGFR4, the native FGFR4 and the formed 8-FGFR4 complex were desalted using HPLC (Agilent 1100) in order to remove excess of ligand. Separation was achieved using a Poros R1/H 2.1 mm x 100 mm (Dr. Maisch, Ammerbuch-Entringen, Germany). The column was kept at 80 °C and flow was 200 µl/min. A gradient from 20% B to 90% B was run in 20 minutes (eluent A: water with 0.1% trifluoroacetic acid, eluent B: 90% acetonitrile with 0.1% trifluoroacetic acid). Peaks corresponding to the modified and unmodified protein were collected and dried under an argon stream. Fractions were suspended in 10 µl 8M urea, 0.3M NH 4 HCO 3 pH8.0, incubated with 1 µl 1M dithiothreitol (reduction) at 56 °C for 30 minutes, and finally incubated with 1 µl of 1M iodoacetamide (alkylation) in the dark, at room temperature for 30 minutes. Samples were diluted with water to achieve a final urea concentration of 0.8M. The pH was adjusted to pH8.0 with 1 µl 1M Tris pH10. Finally, trypsin (Promega V5111) was added (protein:enzyme ratio 1:20) and the samples were incubated overnight at 37 °C. Tryptic peptides from native FGFR4 and 8-FGFR4 complex were analyzed by LC-MS/MS using a UPLC interfaced to a Waters Synapt mass spectrometer (Waters, Milford, MA). The chromatographic separation was carried out on a C 18 reversed-phase column (Acquity UPLC BEH C18, 1 x 50 mm, Waters) at a flow rate of 0.12 ml/min. Column was kept at 40 °C and a chromatographic gradient from 0 to 40% B was run in 60 minutes (eluent A: water with 0.1% formic acid, eluent B: acetonitrile with 0.1% formic acid). MS and MS E spectra were acquired over a mass range of 500-2000 m/z with a scan time of 0.5 s.
Peptides covalently modified with 8 were identified by comparing the peptide maps from native FGFR4 and 8-FGFR4 complex, respectively. The specific 8 fragment 248.15 m/z, generated in MS E was used to identify modified peptides in the ESI-LC-MSMS analysis (Fig. S9) . The tryptic peptide containing the free P-loop cysteine Cys477 of FGFR4 was only detected in samples derived from the native FGFR4 protein.
The peptide containing the modified cysteine Cys477 in the P-loop (main site) and the peptide containing a modified cysteine on residue Cys552 in the middle-hinge region were detected in the sample derived from 8-FGFR4 complex, Figures S10 and S11. Figure S11 . MS E of modified peptide containing hinge region cysteine-552.
FGFR4 X-ray structure determinations
FGFR4 purification: The crystal structure of 8 in complex with FGFR4 was obtained with an FGFR4 construct comprising residues from 449 to 753 (Uniprot P22455) with a K506A mutation and with an Nterminal 6XHis tag followed by a PreScission cleavage site. The crystal structure of 9 in complex with FGFR4 was obtained with an FGFR4 construct comprising residues from 449 to 753 with an N-terminal 6XHis tag followed by a PreScission cleavage site. The purification of both modified FGFR4 constructs were carried out in the same way. Briefly FGFR4 expressed intracellularly in Sf9 cells was homogenized by Frenchpress and first purified by NiNTA affinity chromatography. Following Precision and phosphatase treatment at 4 °C for 18 h, protein was further purified by Mono-Q chromatography, and finally polished by Superdex75 gel filtration chromatography.
Crystallization: Purified FGFR4 protein in buffer (20 mM TRIS, 150 mM NaCl, 3M TCEP, 1 mM EDTA, pH8.0) was mixed with 8 or 9 in excess and concentrated to 5.8 mg/ml and 10 mg/ml, respectively, and was set up for crystallization with method of vapor diffusion by 1:1 mixing with reservoir solution in a total size of 0.4 ul at 294 K. The initial crystals, which typically did not diffract well, were crushed and used for matrix seeding. The well-diffracting crystals for 8 in complex with FGFR4 were obtained in condition containing 0.2M Lithium Sulfate monohydrate, 0.1M Bis-Tris and 25% PEG3350, while the well-diffracting crystals for 9 were obtained in condition containing 0.2M Lithium Sulfate and 25% PEG3350. 10% glycerol was used as cryo-protectant for both complex crystals which were directly flash cooled in liquid nitrogen for data collection.
Structure determination: Diffraction data for both complex crystals were collected at Swiss Light Source (Villigen, Switzerland) at the beam of PXII with a Pilatus pixel detector using x-ray radiation wavelength of 1 Å. The collected data were processed by XDS and XSCALE and the structure was resolved with molecular replacement method with the program PHASER by using an internal unpublished Apo FGFR4 as search model. Iterative model building and refinement were performed with the programs Coot and AUTOBUSTER. Key parameters are included in Table S7 .
The structures are deposited with the Worldwide Protein Data Bank: . Circles indicate the one detected peptide in HUH7 cells (QFSLESGSSGK) that is not shared between isoforms 1 and 2. This peptide shows significantly higher H/L ratios (log2ratio of 0.8 at 1h and 3.6 at 4h), suggesting that the graph underestimates the actual turnover. Three unique peptides for isoform 2 ([TK]SPTLQFSLESGSSGK and IPHLTCDSLTPAGR) were not consistently detected in all samples (not shown), but their H/L ratios suggest a half-life for isoform 2 of 8 h or more (H/L log2ratio of -2.5 at 2 h, n=4).
Compound 10 X-ray structure determination
The crystal data for compound 10 have been deposited with the Cambridge Crystallographic Data Centre, CIF: 1546562.
